Literature DB >> 30536630

Measurement of extended half-life recombinant factor IX products in clinical practice.

Annette E Bowyer1, M Fiona Shepherd1, Steve Kitchen1, Rhona M Maclean2, Mike Makris1,3.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30536630     DOI： 10.1111/ijlh.12953

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN： 1751-5521            Impact factor:   2.877


× No keyword cloud information.
  4 in total

1.  Performance of factor IX extended half-life product measurements in external quality control assessment programs.

Authors:  Angelique Nederlof; Steve Kitchen; Piet Meijer; Marjon Cnossen; Nae Ali Pour; Geoffrey Kershaw; Ian Jennings; Isobel Walker; Moniek P M de Maat
Journal:  J Thromb Haemost       Date:  2020-06-10       Impact factor: 5.824

Review 2.  International consensus recommendations on the management of people with haemophilia B.

Authors:  Daniel P Hart; Davide Matino; Jan Astermark; Gerard Dolan; Roseline d'Oiron; Cédric Hermans; Victor Jiménez-Yuste; Adriana Linares; Tadashi Matsushita; Simon McRae; Margareth C Ozelo; Sean Platton; Darrel Stafford; Robert F Sidonio; Andreas Tiede
Journal:  Ther Adv Hematol       Date:  2022-04-02

3.  Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.

Authors:  Jurg M Sommer; Ali Sadeghi-Khomami; Christopher Barnowski; Margareta Wikén; Annemieke J Willemze
Journal:  Int J Lab Hematol       Date:  2020-03-23       Impact factor: 2.877

4.  Activity measurements of dalcinonacog alfa.

Authors:  Stella C Williams; Elaine Gray
Journal:  Haemophilia       Date:  2020-03-06       Impact factor: 4.287
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.